Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM08TH3)

Drug Name

ITI-214 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Parkinson disease	8A00.0	Phase 1/2	[1]
Complete androgen insensitivity syndrome	LD2A.4	Phase 1	[2]
Immune dysregulation	4A01.2	Phase 1	[2]
Schizophrenia	6A20	Phase 1	[3]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Phosphodiesterase 1 (PDE1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vinpocetine	DMVN2E6	Ischemic stroke	8B11.5Z	Approved	[4]
ZAPRINAST	DMGH3T5	N. A.	N. A.	Terminated	[5]
BIBW-22	DMXIH3Q	Solid tumour/cancer	2A00-2F9Z	Terminated	[6]
isobutylmethylxanthine	DM46F5X	Discovery agent	N.A.	Investigative	[7]
S,S-(2-Hydroxyethyl)Thiocysteine	DMLPAD8	Discovery agent	N.A.	Investigative	[8]
BUFROLIN	DM61F5W	Discovery agent	N.A.	Investigative	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT03257046) Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036537)
4	Effects of phosphodiesterase inhibitors on contraction induced by endothelin-1 of isolated human prostatic tissue. Urology. 2009 Jun;73(6):1397-401.
5	The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. J Med Chem. 2005 May 19;48(10):3449-62.
6	BIBW22 BS, potent multidrug resistance-reversing agent, binds directly to P-glycoprotein and accumulates in drug-resistant cells. Mol Pharmacol. 1996 Sep;50(3):482-92.
7	A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45.
8	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.